Paxlovid

In response to the clinical treatment needs of novel coronavirus infection, small-molecule antiviral drugs have always been one of the core prevention and control tools. As an oral antiviral compound preparation of 3CL protease inhibitor, Paxlovid inhibits the activity of 3CL protease of SARS-CoV-2 in a targeted manner, blocks the cleavage process of polyproteins required for viral replication, and thus reduces the viral load in the body. Its indication is the treatment of adults with mild to moderate novel coronavirus infection who have high risk factors for progression to severe disease. The applicable population covers high-risk groups for severe disease such as the elderly, people with chronic underlying diseases, and people with immunodeficiency, and it can significantly reduce the risk of hospitalization or death.

Since the global prevalence of COVID-19, the market demand for Paxlovid has shown a phased growth characteristic along with the fluctuation of the epidemic, and its global sales once exceeded 18.9 billion US dollars in 2022. In the post-epidemic era, its market demand has gradually shifted to the protection scenarios of key populations, and the competitive landscape is characterized by the dominance of the original research drug and the layout of a number of generic drug enterprises. A number of domestic 3CL protease inhibitors targeting the same target have entered the late clinical stage or the marketing application stage, and the market increment space is mainly concentrated in primary medical care and preventive medication scenarios for key populations.

The original research enterprise of Paxlovid is Pfizer, with the trade name Paxlovid. The expiration date of its core compound patent in China is 2031, and the expiration date of the core patent in the US market is 2030. The dosage form approved for the original research drug is tablet, with the specification of each tablet containing 150 mg nirmatrelvir and 100 mg ritonavir. It has been included in the *Catalogue of Reference Preparations of Chemical Drugs* issued by NMPA, and also included in the FDA reference preparation catalogue. Up to now, a number of domestic enterprises have obtained the CDE API registration number for Paxlovid API, and the original research preparation and a number of domestic generic preparations have been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for Paxlovid, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully meet the compliance requirements of multiple regulations including Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for relevant API R&D, quality research and production enterprises.